Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.


AdvaMed Survey Data Shows MedTech Industry Poised for Greater Investment and Growth with Full Device Tax Repeal

medical-device-tax-23Washington, DC, January 12, 2017 — Medical technology companies are leveraging the 2015 suspension of the medical device excise tax to expand their businesses and investments, according to a new survey from the Advanced Medical Technology Association (AdvaMed).

The study explored various impacts from the tax’s suspension — from job retention and creation to elevated R&D infusions — and suggests a broad range of strong economic activity. Industry analysts believe, however, greater economic growth would occur with permanent device tax repeal.

“Our members are bullish on future industry growth and job creation, as these numbers indicate,” said AdvaMed President and CEO Scott Whitaker. Continue reading

AdvaMed’s MedTech Conference Honors Green Sun Medical as 2016 MedTech Innovator Winner

advamed-logo-croppedWashington, DC, November 8, 2016 — AdvaMed 2016: The MedTech Conference, the leading event for medical technology professionals in North America, and MedTech Innovator named Green Sun Medical the first place winner of the global competition and awarded the company a $200,000 cash prize.

The honor was announced during the Advanced Medical Technology Association’s (AdvaMed) 2016 MedTech Conference, which was held October 17-19 in Minneapolis, MN.

Held in partnership with AdvaMed Accel, MedTech Innovator is the medtech industry’s global competition and virtual accelerator that identifies and accelerates the development of transformative innovations. Continue reading

AdvaMed, MITA and MDMA Commend Congress for Including Suspension of the Medical Device Tax in Year-End Legislation

Capitol Dome flag faveWashington, DC, December 16, 2015 ― The Advanced Medical Technology Association (AdvaMed), the Medical Imaging & Technology Alliance (MITA) and the Medical Device Manufacturers Association (MDMA) today commended Congress for including suspension of the medical device excise tax in year-end legislation and urged its swift passage.

“We are extremely appreciative of the bipartisan efforts to include a two-year suspension of the medical device tax in the tax extenders legislation. Suspending the tax will be an important step in addressing the harmful effect it is having on research and development and continued medical progress.  On behalf of America’s medical technology companies, our employees and the patients we serve, we urge Congress to act swiftly on this legislation,” said AdvaMed Board Chairman Vincent A. Forlenza, chairman, CEO and president BD. Continue reading

AdvaMed Honors Dr. Thomas J. Fogarty with Lifetime Achievement Award

Washington, DC, October 8, 2015 ― The Advanced Medical Technology Association (AdvaMed) today bestowed the third annual AdvaMed Lifetime Achievement Award to internationally renowned cardiovascular surgeon, innovator and entrepreneur Thomas J. Fogarty, MD, inventor of the balloon catheter that is now used in more than 300,000 procedures worldwide each year.

AdvaMed’s Lifetime Achievement Award highlights the accomplishments of a pioneer in the medical technology sector whose contributions have had a significant impact on patients’ lives and the industry as an essential part of America’s economy.  This award recognizes Dr. Fogarty’s achievements and unparalleled leadership in medical innovation, public engagement and mentorship to aspiring entrepreneurs. Continue reading

AdvaMed Leadership Kicks-Off AdvaMed 2015 Conference in San Diego

AdvaMed 2015San Diego, CA, October 5, 2015 ― Advanced Medical Technology Association (AdvaMed) Board Chairman Vincent A. Forlenza, chairman, CEO and president BD, and Stephen J. Ubl, president and CEO of AdvaMed today kicked-off AdvaMed 2015 in San Diego, California.

Forlenza and Ubl launched the conference—the nation’s premier medical technology event—with an update on several key policy issues and an overview of two new studies demonstrating the value of advanced medical technology to the health system, to patients and to the broader economy. Continue reading

AdvaMed Releases Member Survey of Medical Device Tax’s Negative Impact on Companies’ Jobs, R&D

Washington, DC, January 28, 2015 ― The Advanced Medical Technology Association (AdvaMed) today released the results of a new survey that details the negative and costly impact of the medical device tax, reflecting the tough choices companies are making to address it including reducing jobs, research and development (R&D) and other financial investments.

As a follow up to a survey completed in November 2013, AdvaMed conducted a survey of member companies at the end of 2014 to assess the ongoing effects of the medical device tax. The responses to the survey were generalized to the industry as a whole based on the ratio of revenues of responding companies to revenues of the overall industry. Continue reading

MITA, AdvaMed & MDMA Support Bipartisan Efforts in U.S. House to Repeal 2.3% Device Tax

Washington, DC, January 8, 2015 ― The Medical Imaging & Technology Alliance (MITA), Advanced Medical Technology Association (AdvaMed) and the Medical Device Manufacturers Association (MDMA) yesterday applauded the introduction of bipartisan legislation to repeal the 2.3 percent medical device excise tax.

The legislation, H.R. 160 “The Protect Medical Innovation Act,” was sponsored by Reps. Erik Paulsen (R-MN) and Ron Kind (D-WI), and was introduced with 254 original cosponsors.

“Repealing the medical device tax is critical for the United States to maintain its global leadership in this high-tech manufacturing sector and to allocate resources toward the development of new cutting-edge technologies. This tax on innovation stymies the search for cures and treatments and stalls job creation,” said Stephen J. Ubl, President and CEO of AdvaMed. Continue reading

BD CEO Vincent Forlenza Named Chairman of AdvaMed Board of Directors

Washington, DC, December 18, 2014 ― The Advanced Medical Technology Association (AdvaMed) has announced that BD Chairman, President and CEO Vincent A. Forlenza has been named chairman of the AdvaMed Board of Directors for a two-year term.   Forlenza succeeds Covidien Chairman, President and CEO Joe E. Almeida.

Forlenza has served on both the AdvaMed Board and its Executive Committee since 2010 and is the current chair of the association’s Board Committee on Technology and Regulation.   Continue reading

AdvaMed Survey Reveals Impact of Medical Device Tax; Job Loss, Reduction in R&D

Washington, DC, February 19, 2014 — The Advanced Medical Technology Association (AdvaMed) yesterday released new survey results examining the first-year impact of the medical device excise tax.  The survey found a significant reduction in jobs, R&D, and U.S. investment. 

To provide information on the real-world impact of the tax in the first full year of implementation, AdvaMed conducted an online survey of member companies at the end of 2013.  The survey responses were generalized to the industry as a whole based on the ratio of revenues of responding companies to revenues of the overall industry. Continue reading

President Proposes Cuts to Healthcare Industries; Life Sciences Industry Responds

Washington, DC, April 11, 2013 — Yesterday, President Obama unveiled his Fiscal Year 2014 proposed budget, which includes deep cuts in Medicare payments to pharmaceutical companies, hospitals and nursing homes.  Obama’s budget includes roughly $400 billion in healthcare savings — the vast majority of which come from cuts to healthcare providers, rather than changes in benefits.

According to The Hill, the pharmaceutical industry would take a hit of nearly $150 billion under Obama’s budget.  The President proposed steep cuts in the prices Medicare pays for prescription drugs, as well as policies that would speed cheaper generic drugs to market more quickly. Continue reading